Johnson & Johnson (JNJ) vs Novartis AG (NVS)
- Johnson & Johnson JNJ 270.98 +1.45%
- Novartis AG NVS 151.95 +0.49%
Johnson & Johnson and Novartis AG are both Drug Manufacturers General companies. Johnson & Johnson is the larger, with a market value of $650.7B against $277.7B — 2.3× the size. Novartis AG trades at the lower P/E: 28.8× against 40.5×. Johnson & Johnson grew revenue faster over the last twelve months: 7.80% against 1.76%. Novartis AG has the higher net margin (17.5% vs 16.2%) and the higher return on invested capital (12.1% vs 11.1%). Both pay a dividend; Novartis AG yields more (3.13% vs 1.98%). Across the 23 metrics below, Novartis AG leads on 16 and Johnson & Johnson on 7.
Valuation
Profitability
| Metric | JNJ | NVS | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 67.56% | 74.92% | 73.01% |
| Operating margin | 19.72% | 25.18% | 18.34% |
| Net margin | 16.20% | 17.49% | 7.31% |
| Free cash flow margin | 21.13% | 24.66% | 18.56% |
| Return on equity | 20.02% | 24.37% | 20.02% |
| Return on assets | 8.25% | 8.94% | 2.28% |
| Return on invested capital | 11.07% | 12.05% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack